Clinical trial
A Phase 2A Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose Ranging Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
NCT04847440 is registered in ClinicalTrials.gov with Antios Therapeutics, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2A Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose Ranging Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
- Lead sponsor
- Antios Therapeutics, Inc
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 30, 2021
- Completion date
- September 1, 2022
- Enrollment
- 40 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.